vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Pathfinder Bancorp, Inc. (PBHC). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $11.8M, roughly 1.1× Pathfinder Bancorp, Inc.). On growth, Pathfinder Bancorp, Inc. posted the faster year-over-year revenue change (-22.6% vs -57.9%). Over the past eight quarters, Pathfinder Bancorp, Inc.'s revenue compounded faster (3.0% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Pathfinder Bancorp, Inc. is a regional bank holding company headquartered in New York, U.S. It operates Pathfinder Bank serving the central New York market, offering retail and commercial banking services including deposit accounts, mortgages, business loans and wealth management for individual consumers and small to medium-sized enterprises.

ASRT vs PBHC — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.1× larger
ASRT
$13.5M
$11.8M
PBHC
Growing faster (revenue YoY)
PBHC
PBHC
+35.3% gap
PBHC
-22.6%
-57.9%
ASRT
Faster 2-yr revenue CAGR
PBHC
PBHC
Annualised
PBHC
3.0%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
PBHC
PBHC
Revenue
$13.5M
$11.8M
Net Profit
$-5.6M
Gross Margin
Operating Margin
-86.7%
-81.1%
Net Margin
-52.9%
Revenue YoY
-57.9%
-22.6%
Net Profit YoY
-242.4%
EPS (diluted)
$-4.54

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
PBHC
PBHC
Q4 25
$13.5M
$11.8M
Q3 25
$49.5M
$13.1M
Q2 25
$29.2M
$9.3M
Q1 25
$26.5M
$12.6M
Q4 24
$32.2M
$15.3M
Q3 24
$29.2M
$13.4M
Q2 24
$31.1M
$10.7M
Q1 24
$32.4M
$11.1M
Net Profit
ASRT
ASRT
PBHC
PBHC
Q4 25
$-5.6M
Q3 25
$11.4M
$626.0K
Q2 25
$-16.4M
$31.0K
Q1 25
$-13.5M
$3.0M
Q4 24
$3.9M
Q3 24
$-2.9M
$-4.6M
Q2 24
$-3.7M
$2.0M
Q1 24
$-4.5M
$2.1M
Operating Margin
ASRT
ASRT
PBHC
PBHC
Q4 25
-86.7%
-81.1%
Q3 25
23.2%
5.1%
Q2 25
-27.5%
0.4%
Q1 25
-50.0%
29.5%
Q4 24
-41.9%
55.4%
Q3 24
-10.4%
-43.1%
Q2 24
-11.6%
23.3%
Q1 24
-13.4%
24.3%
Net Margin
ASRT
ASRT
PBHC
PBHC
Q4 25
-52.9%
Q3 25
23.1%
4.8%
Q2 25
-56.0%
0.3%
Q1 25
-51.1%
23.6%
Q4 24
37.7%
Q3 24
-10.0%
-34.6%
Q2 24
-11.8%
18.7%
Q1 24
-13.9%
19.0%
EPS (diluted)
ASRT
ASRT
PBHC
PBHC
Q4 25
$-4.54
Q3 25
$0.11
$0.47
Q2 25
$-0.17
$0.47
Q1 25
$-0.14
Q4 24
$-3.28
Q3 24
$-0.03
$0.41
Q2 24
$-0.04
$0.41
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
PBHC
PBHC
Cash + ST InvestmentsLiquidity on hand
$63.4M
Total DebtLower is stronger
$14.1M
Stockholders' EquityBook value
$94.0M
$122.5M
Total Assets
$267.0M
$1.4B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
PBHC
PBHC
Q4 25
$63.4M
Q3 25
$93.4M
Q2 25
$98.2M
Q1 25
$87.3M
Q4 24
$100.1M
Q3 24
$88.6M
Q2 24
$88.4M
Q1 24
$80.7M
Total Debt
ASRT
ASRT
PBHC
PBHC
Q4 25
$14.1M
Q3 25
$18.7M
Q2 25
$21.0M
Q1 25
$17.6M
Q4 24
$27.1M
Q3 24
$39.8M
Q2 24
$45.9M
Q1 24
$38.6M
$45.9M
Stockholders' Equity
ASRT
ASRT
PBHC
PBHC
Q4 25
$94.0M
$122.5M
Q3 25
$105.8M
$126.3M
Q2 25
$93.3M
$124.4M
Q1 25
$108.5M
$124.9M
Q4 24
$121.1M
$121.5M
Q3 24
$130.5M
$120.2M
Q2 24
$132.2M
$123.3M
Q1 24
$134.5M
$121.8M
Total Assets
ASRT
ASRT
PBHC
PBHC
Q4 25
$267.0M
$1.4B
Q3 25
$319.8M
$1.5B
Q2 25
$273.8M
$1.5B
Q1 25
$286.4M
$1.5B
Q4 24
$284.7M
$1.5B
Q3 24
$276.0M
$1.5B
Q2 24
$279.4M
$1.4B
Q1 24
$282.0M
$1.5B
Debt / Equity
ASRT
ASRT
PBHC
PBHC
Q4 25
0.11×
Q3 25
0.15×
Q2 25
0.17×
Q1 25
0.14×
Q4 24
0.22×
Q3 24
0.33×
Q2 24
0.37×
Q1 24
0.29×
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
PBHC
PBHC
Operating Cash FlowLast quarter
$-30.0M
$11.7M
Free Cash FlowOCF − Capex
$10.4M
FCF MarginFCF / Revenue
88.1%
Capex IntensityCapex / Revenue
10.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$18.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
PBHC
PBHC
Q4 25
$-30.0M
$11.7M
Q3 25
$-4.8M
$7.0M
Q2 25
$19.1M
$-3.7M
Q1 25
$-12.5M
$5.7M
Q4 24
$11.5M
$11.2M
Q3 24
$-35.0K
$11.8M
Q2 24
$7.4M
$1.5M
Q1 24
$7.5M
$504.0K
Free Cash Flow
ASRT
ASRT
PBHC
PBHC
Q4 25
$10.4M
Q3 25
$6.9M
Q2 25
$-4.0M
Q1 25
$5.1M
Q4 24
$9.1M
Q3 24
$11.3M
Q2 24
$637.0K
Q1 24
$274.0K
FCF Margin
ASRT
ASRT
PBHC
PBHC
Q4 25
88.1%
Q3 25
52.8%
Q2 25
-42.6%
Q1 25
40.1%
Q4 24
59.9%
Q3 24
84.3%
Q2 24
6.0%
Q1 24
2.5%
Capex Intensity
ASRT
ASRT
PBHC
PBHC
Q4 25
10.7%
Q3 25
1.0%
Q2 25
2.4%
Q1 25
5.1%
Q4 24
13.5%
Q3 24
0.0%
3.8%
Q2 24
8.2%
Q1 24
2.1%
Cash Conversion
ASRT
ASRT
PBHC
PBHC
Q4 25
Q3 25
-0.42×
11.26×
Q2 25
-120.55×
Q1 25
1.92×
Q4 24
2.87×
Q3 24
Q2 24
0.76×
Q1 24
0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

PBHC
PBHC

Other$5.6M47%
Banking$3.7M31%
Deposit Account$1.5M13%
Financial Service Other$1.0M9%

Related Comparisons